We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Tiziana Life Sciences plc Ordinary 3p

Sell:58.50p Buy:58.50p Change: No change
Market closed |  Prices as at close on 31 December 2021 | Switch to live prices |
Scheme of Arrangement

Tiziana Life Sciences plc Ordinary 3p

Type:
Scheme of Arrangement
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 17 Sep 2021)

Tiziana Life Sciences is proposing to convert to a Bermuda incorporated company with its shares listed on the NASDAQ stock market in the US. You’ll receive 1 share in the new Bermuda incorporated Tiziana Life Sciences in place of every 2 shares held.

 

As part of the plan, the shares will be delisted from the London Stock Exchange (LSE) on 21 October 2021. From this date, it will only be possible to trade the shares on NASDAQ. The deadline to sell your shares on the LSE via Hargreaves Lansdown is 4.30pm on Friday 15 October 2021.

 

Shareholders will vote on the proposal at meetings on 27 September 2021. 

 

You’ll need to do this by noon on Wednesday 22 September 2021 so we can pass your vote onto the company before the shareholder meetings.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

 

×
Sell:58.50p
Buy:58.50p
Change: No change
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Market closed |  Prices as at close on 31 December 2021 | Switch to live prices |
Scheme of Arrangement

Tiziana Life Sciences plc Ordinary 3p

Type:
Scheme of Arrangement
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 17 Sep 2021)

Tiziana Life Sciences is proposing to convert to a Bermuda incorporated company with its shares listed on the NASDAQ stock market in the US. You’ll receive 1 share in the new Bermuda incorporated Tiziana Life Sciences in place of every 2 shares held.

 

As part of the plan, the shares will be delisted from the London Stock Exchange (LSE) on 21 October 2021. From this date, it will only be possible to trade the shares on NASDAQ. The deadline to sell your shares on the LSE via Hargreaves Lansdown is 4.30pm on Friday 15 October 2021.

 

Shareholders will vote on the proposal at meetings on 27 September 2021. 

 

You’ll need to do this by noon on Wednesday 22 September 2021 so we can pass your vote onto the company before the shareholder meetings.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

 

×
Sell:58.50p
Buy:58.50p
Change: No change
Market closed |  Prices as at close on 31 December 2021 | Switch to live prices |
Scheme of Arrangement

Tiziana Life Sciences plc Ordinary 3p

Type:
Scheme of Arrangement
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 17 Sep 2021)

Tiziana Life Sciences is proposing to convert to a Bermuda incorporated company with its shares listed on the NASDAQ stock market in the US. You’ll receive 1 share in the new Bermuda incorporated Tiziana Life Sciences in place of every 2 shares held.

 

As part of the plan, the shares will be delisted from the London Stock Exchange (LSE) on 21 October 2021. From this date, it will only be possible to trade the shares on NASDAQ. The deadline to sell your shares on the LSE via Hargreaves Lansdown is 4.30pm on Friday 15 October 2021.

 

Shareholders will vote on the proposal at meetings on 27 September 2021. 

 

You’ll need to do this by noon on Wednesday 22 September 2021 so we can pass your vote onto the company before the shareholder meetings.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

 

×
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its lead product candidates include Milciclib (TZLS-201) and Foralumab (TZLS-401). Its products also include Anti IK-6r (TZLS-501) and StemPrintER. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib has completed Phase IIa trials as a monotherapy for the treatment for thymic carcinoma and hepatocellular carcinoma (HCC). The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. Foralumab has completed Phase II trial and has potential application in a wide range of autoimmune and inflammatory diseases.

Contact details

Address:
3rd Fl, 11/12 St. James's Square
LONDON
SW1Y 4LB
United Kingdom
Telephone:
+44 (020) 74952379
Website:
https://www.tizianalifesciences.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

EPIC:
n/a
ISIN:
GB00BKWNZY55
Market cap:
n/a
Shares in issue:
n/a
Sector:
n/a
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Gabriele Cerrone
    Executive Chairman of the Board
  • Shailubhai Kunwar
    Chief Executive Officer, Chief Scientific Officer, Director
  • Tiziano Lazzaretti
    Chief Financial Officer
  • James Tripp
    Chief Operating Officer, Head of Global Clinical Operations
  • Thomas Adams
    Executive Director
  • Neil Graham
    Chief Medical Officer
  • P. Cooper
    Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Hargreaves Lansdown.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.